Imaging software developer Mirada Medical and BTG are collaborating to develop dosimetry software for radioembolization therapy.
The companies are working together to provide a more personalized approach to radioembolization for liver cancer patients using BTG's TheraSphere, which delivers yttrium-90 via small microspheres.
Mirada and BTG plan to make the software available in 2016.
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
